Accelerate Diagnostics Inc.’s recently made public that its Chief Technology Officer Mertz Larry Michael unloaded Company’s shares for reported $16366.0 on Mar 02. In the deal valued at $0.49 per share,33,401 shares were sold. As a result of this transaction, Mertz Larry Michael now holds 516,339 shares worth roughly $ 0.26 million.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Then, Phillips Jack sold 8,601 shares, generating $5,161 in total proceeds. Upon selling the shares at $0.60, the Chief Executive Officer now owns 269,458 shares.
Before that, REICHLING STEVEN sold 4,823 shares. Accelerate Diagnostics Inc. shares valued at $2,894 were divested by the Chief Financial Officer at a price of $0.60 per share. As a result of the transaction, REICHLING STEVEN now holds 76,818 shares, worth roughly $38409.0.
Craig Hallum downgraded its Accelerate Diagnostics Inc. [AXDX] rating to a Hold from a a Buy in a research note published on Monday. PT values the company’s stock at a premium of 90.0 to its Monday closing price. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in early October with a ‘”a Neutral”‘ rating. Craig Hallum also remained covering AXDX and has increased its forecast on August 07, 2020 with a “Buy” recommendation from previously “Hold” rating. JP Morgan revised its rating on September 27, 2019. It rated AXDX as “an Underweight” which previously was an “a Neutral”.
Price Performance Review of AXDX
On Monday, Accelerate Diagnostics Inc. [NASDAQ:AXDX] saw its stock fall -6.42% to $0.50. On the same session, the stock had its day’s lowest price of $0.4799, but rose to a high of $0.53. Over the last five days, the stock has gained 7.83%. Accelerate Diagnostics Inc. shares have fallen nearly -29.75% since the year began. Nevertheless, the stocks have fallen -79.92% over the past one year. While a 52-week high of $3.74 was reached on 01/24/23, a 52-week low of $0.46 was recorded on 02/27/23. SMA at 50 days reached $0.6315, while 200 days put it at $1.1281. A total of 0.55 million shares were traded, compared to the trading of 0.36 million shares in the previous session.
Levels Of Support And Resistance For AXDX Stock
The 24-hour chart illustrates a support level at 0.4739, which if violated will result in even more drops to 0.4519. On the upside, there is a resistance level at 0.5240. A further resistance level may holdings at 0.5521. The Relative Strength Index (RSI) on the 14-day chart is 35.37, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0293, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 83.22%. Stochastics %K at 22.85% indicates the stock is a holding.
How much short interest is there in Accelerate Diagnostics Inc.?
A steep rise in short interest was recorded in Accelerate Diagnostics Inc. stocks on Jan 12, 2023, growing by 0.13 million shares to a total of 4.46 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2022 was 4.33 million shares. There was a rise of 2.91%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 6.29% of the overall stock float, the days-to-cover ratio (short ratio) rose to 12.52.
According to FactSet, Accelerate Diagnostics Inc.’s share price will average $2.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 277.36 percent from its previous closing price of $0.53. Analysts expect Accelerate Diagnostics Inc. stock to reach the higher price of $2.00, while the lowest price estimate is $2.00. However, 1 analyst have rated AXDX stock as a Buy in their predictions for 2023.